Common Side Effects of Tzield
Tzield (teplizumab-mzwv), approved for delaying type 1 diabetes onset in at-risk individuals, causes mostly mild to moderate reactions tied to its IV infusion. These include headache (affecting 29% of patients), rash (25%), nausea (21%), fatigue (20%), and fever (18%). Lymphopenia, a drop in lymphocytes, hits 65% during treatment and persists in some cases.[1][2]
Serious Side Effects and Risks
Severe reactions occur in under 5% but require monitoring. Cytokine release syndrome appears in 6%, with symptoms like chills, abdominal pain, or throat irritation. Infections rise due to immune suppression—serious ones in 3.5%. Risk of autoimmune disorders, like thyroid issues or type 1 diabetes progression, exists; one trial reported two cases of Guillain-Barré syndrome. Liver enzyme elevations and neutropenia also occur.[1][2][3]
How Side Effects Compare to Placebo
In the pivotal trial, side effects were more frequent with Tzield (94%) than placebo (79%). Infusion reactions drove most differences: 56% with Tzield vs. 22% placebo. Long-term, lymphocyte counts recover but stay lower for months.[2]
What Happens During and After Infusion
Tzield's 14-day course triggers reactions peaking on days 1-3. Premedicate with antihistamines or acetaminophen to reduce them. Post-treatment, monitor blood counts and infections for weeks; avoid live vaccines.[1][3]
Patient Reports and Management
Real-world use shows rashes and fatigue resolve quickly, but some report lingering tiredness. Doctors advise hydration, rest, and prompt reporting of fever or severe rash. Not for active type 1 diabetes patients due to risks.[2][3]
[1] Tzield Prescribing Information, Provention Bio (FDA label), https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761083s000lbl.pdf
[2] NEJM Trial Data (Devlin et al., 2023), https://www.nejm.org/doi/full/10.1056/NEJMoa2208534
[3] Drugs.com Side Effects Summary, https://www.drugs.com/tzield.html